しかし,しかしながら,しかしながら

Same author

Immunoglobulin A vasculitis in association with invasive meningococcal disease: a case report.

Modern rheumatology case reports·2026

Same author

Secukinumab for Giant Cell Arteritis.

NEJM evidence·2026

Same author

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.

The New England journal of medicine·2026

Same author

Feasibility, Safety and Preliminary Efficacy of 1:1 THC:CBD Cannabis Oil for Fibromyalgia Symptoms: Results From a Randomised, Double-Blind, Placebo-Controlled Pilot Trial.

Pain research & management·2026

Same author

Assessing the feasibility and acceptance of the Deaf in Touch Everywhere (DITE™) mobile app: Insights from healthcare simulations and stakeholder discussions (HEARD project).

Digital health·2026

Same author

An updated and expanded characterization of the biological sciences academic job market.

Frontiers in research metrics and analytics·2024

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

関連する実験動画

しかし,しかしながら,しかしながら

関連する概念動画

Immunoglobulin A vasculitis in association with invasive meningococcal disease: a case report.

Secukinumab for Giant Cell Arteritis.

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.

Feasibility, Safety and Preliminary Efficacy of 1:1 THC:CBD Cannabis Oil for Fibromyalgia Symptoms: Results From a Randomised, Double-Blind, Placebo-Controlled Pilot Trial.

Assessing the feasibility and acceptance of the Deaf in Touch Everywhere (DITE™) mobile app: Insights from healthcare simulations and stakeholder discussions (HEARD project).

An updated and expanded characterization of the biological sciences academic job market.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

関連する実験動画

しかし,しかしながら,しかしながら

関連する概念動画

関連記事

Immunoglobulin A vasculitis in association with invasive meningococcal disease: a case report.

Secukinumab for Giant Cell Arteritis.

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.

Feasibility, Safety and Preliminary Efficacy of 1:1 THC:CBD Cannabis Oil for Fibromyalgia Symptoms: Results From a Randomised, Double-Blind, Placebo-Controlled Pilot Trial.

Assessing the feasibility and acceptance of the Deaf in Touch Everywhere (DITE™) mobile app: Insights from healthcare simulations and stakeholder discussions (HEARD project).

An updated and expanded characterization of the biological sciences academic job market.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.